eric topol glp-1 Could drugs be used to fight Alzheimer's disease? Dr. Topol, author of “Super Agers,” explains the possibilities. #Amanpour #AmanpourPBS #pbs How to Extend Your Healthspan

Clinical trial data for FDA-approved GLP-1 receptor agonists demonstrates: Significant weight reduction: Meaningful mean body weight reduction in trial participants (see FDA-approved labeling for specific approved products) Cardiorenal protection: Reduced risk of major adverse cardiovascular events and kidney disease progression Improved lipid profiles: Decreased triglycerides and increased HDL cholesterol Blood pressure reduction: Modest but clinically significant decreases in systolic blood pressure Reduced inflammation: Decreased inflammatory markers associated with metabolic syndrome Note: Clinical outcomes cited above reflect published trial data for FDA-approved GLP-1 receptor agonists

The resistance against O

Results We included 1,647,238 patients who were prescribed a GLP-1 RA between January 2024 and July 2025, with 6,059,445 total GLP-1 RA prescriptions during this period

For best results use at a .5% to 2% concentration, keep in mind 2% is the maximum suggested concentration level for this product